Deals
Celgene’s $7.2 Billion Deal Buys Time for Other Bets to Work
Inside Celgene's Plan to Buy Receptos
This article is for subscribers only.
Celgene Corp.’s $7.2 billion agreement to buy drugmaker Receptos Inc. is the deal it’s been waiting for.
Celgene’s all-cash offer for the startup, announced Tuesday, moves beyond its typical strategy of striking partnerships with other biotechnology companies, many of which are focused on early-stage experimental therapies. The Summit, New Jersey-based company signed more licensing deals last year than any other biotech drugmaker -- 10 in all, according to data compiled by Bloomberg Intelligence.